ELVN — Enliven Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.10bn
- $778.74m
- 30
- 26
- 90
- 46
Annual cashflow statement for Enliven Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -23.5 | -41.4 | -51.4 | 1.49 | -71.6 |
| Depreciation | |||||
| Non-Cash Items | 0.88 | 2.35 | 4 | -32.3 | 8.62 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.673 | 1.51 | 0.514 | -5.36 | 1.4 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -21.9 | -37.4 | -46.8 | -35.6 | -61.3 |
| Capital Expenditures | -0.14 | -0.018 | -0.012 | -0.363 | -0.149 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -23.9 | -16.7 | -1.62 | 76.9 | -148 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -24.1 | -16.7 | -1.63 | 76.5 | -148 |
| Financing Cash Flow Items | -2 | -1.72 | -0.578 | -1.23 | 234 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 43.6 | 96.9 | 49.1 | -1.23 | 234 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.36 | 42.8 | 0.698 | 39.7 | 24.6 |